GRAIL (NASDAQ:GRAL) President Sells $852,820.32 in Stock

GRAIL, Inc. (NASDAQ:GRAL) President Joshua Ofman sold 17,002 shares of the firm’s stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $50.16, for a total transaction of $852,820.32. Following the completion of the sale, the president owned 436,508 shares in the company, valued at $21,895,241.28. This represents a 3.75% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.

GRAIL Trading Down 4.1%

Shares of GRAL opened at $51.80 on Friday. The firm has a market cap of $2.02 billion, a PE ratio of -4.63 and a beta of 5.18. The firm has a fifty day simple moving average of $89.73 and a two-hundred day simple moving average of $77.12. GRAIL, Inc. has a 1-year low of $20.44 and a 1-year high of $118.84.

GRAIL (NASDAQ:GRAL) last released its quarterly earnings results on Thursday, February 19th. The company reported ($2.44) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($3.33) by $0.89. The firm had revenue of $43.60 million for the quarter, compared to the consensus estimate of $43.33 million. GRAIL had a negative return on equity of 17.58% and a negative net margin of 277.46%. As a group, research analysts forecast that GRAIL, Inc. will post -15.15 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the stock. Robert W. Baird set a $82.00 price objective on shares of GRAIL in a research note on Friday, February 20th. Guggenheim increased their price target on shares of GRAIL from $100.00 to $130.00 and gave the stock a “buy” rating in a research report on Monday, January 26th. Canaccord Genuity Group dropped their price target on shares of GRAIL from $105.00 to $80.00 and set a “buy” rating on the stock in a research note on Friday, February 20th. Weiss Ratings restated a “sell (d-)” rating on shares of GRAIL in a research note on Thursday, January 22nd. Finally, TD Cowen started coverage on GRAIL in a report on Thursday, February 19th. They issued a “hold” rating and a $114.00 target price on the stock. Three research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $90.17.

Institutional Investors Weigh In On GRAIL

Institutional investors have recently bought and sold shares of the business. N.E.W. Advisory Services LLC purchased a new position in shares of GRAIL in the fourth quarter valued at about $26,000. Comerica Bank raised its stake in GRAIL by 59.2% during the 3rd quarter. Comerica Bank now owns 465 shares of the company’s stock valued at $27,000 after purchasing an additional 173 shares during the period. Caitong International Asset Management Co. Ltd purchased a new position in GRAIL in the 4th quarter worth approximately $28,000. Elyxium Wealth LLC bought a new position in GRAIL in the 4th quarter worth approximately $31,000. Finally, Intesa Sanpaolo S.p.A. purchased a new stake in GRAIL during the 4th quarter valued at approximately $44,000.

GRAIL Company Profile

GRAIL, Inc (NASDAQ: GRAL) is a biotechnology company dedicated to the early detection of cancer through a multi-cancer blood test. Leveraging advances in next-generation sequencing, cell-free DNA (cfDNA) analysis and machine learning, GRAIL has developed the Galleri™ test, which aims to identify more than 50 types of cancer at their earliest stages. The company’s platform analyzes methylation patterns in circulating tumor DNA to pinpoint tumor presence and tissue of origin, enabling physicians to pursue timely diagnostic follow-up.

Founded in 2016 as a spin-out from Illumina, GRAIL established its headquarters in Menlo Park, California, with additional research and operations centers in the United Kingdom.